Congress orders health agencies to review perimenopause hormone testing evidence

What it does

This bill directs the National Institutes of Health to review existing published evidence on how hormone levels vary in women before perimenopause symptoms appear, and directs the U.S. Preventive Services Task Force to review evidence on whether baseline hormone testing before symptoms helps diagnose or manage perimenopause. Both agencies must report their findings and recommendations to Congress within 18 months. The bill funds no new research directly—it mandates a literature review and evidence assessment to inform future clinical guidance.

Why we flagged it

The bill is a straightforward mandate for federal health agencies to conduct a systematic review of published evidence on perimenopause hormone testing and report findings to Congress. It is a transparency and evidence-gathering mechanism, not a regulatory change or appropriation.

What the text implies

• The 18-month timeline may be tight for a comprehensive evidence review; if agencies cannot complete the work, Congress may face pressure to extend deadlines or appropriate additional resources.
• The bill does not mandate that clinical practice change based on findings—it only requires reporting. Implementation of recommendations depends on downstream action by medical societies, insurers, and providers.

The full analysis lists 3 implications of this text.

Who it affects

Women with perimenopause gain from evidence-based clinical guidance informed by a systematic review of existing research. The bill creates transparency and accountability by requiring federal health agencies to assess what is known about hormone testing and report to Congress, potentially improving clinical decision-making and reducing unnecessary or ineffective testing.